Page 52 - 南京医科大学自然版
P. 52
第44卷第10期
·1368 · 南 京 医 科 大 学 学 报 2024年10月
FR1⁃driven stem cell leukemia/lymphoma syndrome[J]. [18]HUANG C H,LEE Y C,CHIOU J T,et al. Arsenic trioxide⁃
Int J Cancer,2020,146(8):2243-2254 induced p38 MAPK and Akt mediated MCL1 downregula⁃
[10] GU T L,GOSS V L,REEVES C,et al. Phosphotyrosine tion causes apoptosis of BCR ⁃ ABL1 ⁃ positive leukemia
profiling identifies the KG⁃1 cell line as a model for the cells[J]. Toxicol Appl Pharmacol,2020,397:115013
study of FGFR1 fusions in acute myeloid leukemia[J]. [19]MARÍA C E,EVA C,ELENA D B,et al. 2⁃Deoxy⁃D⁃
Blood,2006,108(13):4202-4204 glucose cooperates with arsenic trioxide to induce apopto⁃
[11] CORTES J,APPERLEY J,LOMAIA E,et al. Ponatinib sis in leukemia cells:involvement of IGF ⁃ 1R ⁃ regulated
dose⁃ranging study in chronic⁃phase chronic myeloid leu⁃ Akt/mTOR,MEK/ERK and LKB⁃1/AMPK signaling path⁃
kemia:a randomized,open⁃label phase 2 clinical trial[J]. ways[J]. Biochem Pharmacol,2012,84(12):1604-1616
Blood,2021,138(21):2042-2050 [20]ROBERTS A W,ANDREW H W,DAVID C S. BCL2 and
[12] COUTURIER M A,THOMAS X,RAFFOUX E,et al. MCL1 inhibitors for hematologic malignancies[J]. Blood,
Blinatumomab+ponatinib for relapsed/refractory Philadel⁃ 2021,138(13):1120-1136
phia chromosome⁃positive acute lymphoblastic leukemia [21]GAURAV S C,SAYER A H,ALEXANDRU A. Caspase⁃3
in adults[J]. Leuk Lymphoma,2021,62(3):620-629 activation is a critical determinant of genotoxic stress⁃
[13]CORTES J E,KIM D W,PINILLA⁃IBARZ J,et al. Pona⁃ induced apoptosis[J]. Methods Mol Biol,2015,1219:1-9
tinib efficacy and safety in Philadelphia chromosome⁃posi⁃ [22]XIN P,XU X,DENG C,et al. The role of JAK/STAT sig⁃
tive leukemia:final 5⁃year results of the phase 2 PACE naling pathway and its inhibitors in diseases[J]. Int Im⁃
trial[J]. Blood,2018,132(4):393-404 munopharmacol,2020,80:106210
[14]FIONA H T,TRACY L P,STANLEY S S,et al. Ponatinib: [23] ANNA O,CHRISTINA W,ARAUJO E D,et al. Direct
a novel multi ⁃ tyrosine kinase inhibitor against human targeting options for STAT3 and STAT5 in cancer[J].
malignancies[J]. Onco Targets Ther,2019,12:635-645 Cancers(Basel),2019,11(12):1930-1945
[15]REN M,QIN H,REN R,et al. Ponatinib suppresses the [24]INA K,KIMBERLEY J H IDA S G,et al. The PI3K⁃Akt⁃
development of myeloid and lymphoid malignancies asso⁃ mTOR signaling pathway in human acute myeloid leuke⁃
ciated with FGFR1 abnormalities[J]. Leukemia,2013,27 mia(AML)cells[J]. Int J Mol Sci,2020,21(8):2907-
(1):32-40 2928
[16] MIGUEL A S,PIERRE F,MARTIN S T,et al. Manage⁃ [25]GUO Y J,PAN W W,LIU S B,et al. ERK/MAPK signal⁃
ment of acute promyelocytic leukemia:updated recom⁃ ling pathway and tumorigenesis[J]. Exp Ther Med,2020,
mendations from an expert panel of the European Leuke⁃ 19(3):1997-2007
miaNet[J]. Blood,2019,133(15):1630-1643 [26]ISHWARYA,SIDDHA K,AISHATH N,et al. Activation
[17] WU S F,RAO G,WANG R,et al. The neuroprotective of the MAPK pathway mediates resistance to PI3K inhibi⁃
effect of curcumin against ATO triggered neurotoxicity tors in chronic lymphocytic leukemia[J]. Blood,2021,
throughNrf2 and NF⁃κB signaling pathway in the brain of 138(1):44-56
ducks[J]. Ecotoxicol Environ Saf,2021,228:112965- [收稿日期] 2022-10-21
112974 (本文编辑:蒋 莉)